Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of

Unanswered questions

Important unanswered questions about the use of hypofractionated radiotherapy in early breast cancer are outlined below. Some of these questions may be addressed in ongoing trials:

  • Treatment outcomes for patients who received hypofractionated radiotherapy in relation to age, tumour size and histologic grade
  • Optimal hypofractionated radiotherapy schedule
  • Safety and efficacy of tumour bed boost administered after hypofractionated radiotherapy
  • Safety and efficacy of hypofractionated regional nodal radiotherapy
  • Hypofractionated radiotherapy for DCIS
  • Potential interactions between adjuvant systemic therapies and hypofractionated radiotherapy
  • Long-term effects of hypofractionation on cardiac toxicity
  • Long-term effects of hypofractionation on rib morbidity
  • Psychosocial outcomes for women receiving hypofractionated radiotherapy, including impact of hypofractionated radiotherapy on quality of life, such as side-effects and practical implications of a shorter treatment schedule
  • Health economic considerations of hypofractionated radiotherapy

Published using CeCC Docbook Manager